INmune BioINMB -4.59%52 Quick Ratio is 4.24 as of Mar. 2026, which is 23% below its 10-year median of 5.53. GuruFocus rates INMB with a GF Score™ of 52/100 and a GF Value™ of $1.84 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,417 Biotechnology companies, INmune Bio ranks better than 54.55% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. INmune Bio's quick ratio for the quarter that ended in Mar. 2026 was 4.24.
INmune Bio has a quick ratio of 4.24. It generally indicates good short-term financial strength.
The historical rank and industry rank for INmune Bio's Quick Ratio or its related term are showing as below:
INMB'
s Quick Ratio Range Over the Past 10 Years
Min: 0.75 Med: 5.53 Max: 30.87
Current: 4.24
During the past 10 years, INmune Bio's highest Quick Ratio was 30.87. The lowest was 0.75. And the median was 5.53.
INMB's Quick Ratio is ranked better than 54.55% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs INMB: 4.24
INmune Bio (NAS:INMB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
INmune Bio Quick Ratio Related Terms
INmune Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for INmune Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, INmune Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where INmune Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
INmune Bio's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INmune Bio (INMB) has a Quick Ratio of 4.24 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on INmune Bio and its competitors. This is 23% below median its historical median of 5.53. Over the past decade, INmune Bio's Quick Ratio has ranged from 0.75 to 30.87. According to the industry distribution chart, INmune Bio ranks #644 out of 1417 companies in the Biotechnology industry, placing it in the top 45.4%.
Is INmune Bio's Quick Ratio too high?
INmune Bio's current Quick Ratio of 4.24 is 23% below median its 10-year median of 5.53. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 30.87. The Biotechnology industry median Quick Ratio is 3.60. INmune Bio's value of 4.24 is 17.8% above this industry median. Based on the distribution chart, INmune Bio ranks #644 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, INmune Bio has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Quick Ratio compare to GRDX and VERU?
According to the Biotechnology industry distribution chart, INmune Bio ranks #644 out of 1417 companies for Quick Ratio. This puts INmune Bio in the upper half of its industry. The industry median Quick Ratio is 3.60. INmune Bio's value of 4.24 is 17.8% above this benchmark. Historically, INmune Bio's own Quick Ratio has ranged from 0.75 to 30.87 over the past decade. While the company's 10-year median is 5.53 vs. the industry median of 3.60, INmune Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INmune Bio's current Quick Ratio of 4.24 is 17.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on INmune Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current Quick Ratio is 4.24, which is 23% below median its own 10-year median of 5.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.84, compared to a current price of $1.35 — trading 26.6% below its estimated fair value. The current Quick Ratio is 4.24, which is 23% below median its 10-year median of 5.53 and 17.8% above the Biotechnology industry median of 3.60. INmune Bio's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For INmune Bio (INMB), the current Quick Ratio is 4.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued.
The current stock price of $1.35 is trading 26.6% below its estimated GF Value™ of $1.84.
GuruFocus considers INmune Bio to be Modestly Undervalued.
Key valuation signals for INMB:
Quick Ratio: 4.24 (23% below median its 10-year median of 5.53)
GF Value™: $1.84 vs. price of $1.35 (26.6% below fair value)
Industry Position: 17.8% above the Biotechnology median (#644 of 1417)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
52GF Score
Get the complete analysis for INMB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
